Aardvark Therapeutics

Aardvark Therapeutics, Inc. is a Nasdaq-listed (AARD) clinical-stage biopharmaceutical company developing novel small-molecule therapies designed to inhibit hunger and treat metabolic disease. Its lead candidate, ARD-101, is an oral, gut-restricted agonist of bitter taste receptors (TAS2Rs) on the luminal side of the intestine, which triggers the release of satiety hormones to suppress hunger signaling; it has been evaluated for hyperphagia associated with Prader-Willi Syndrome, including the Phase 3 HERO trial, as well as in obesity and hypothalamic obesity. The company operates purely as a drug-development organization: its public web presence consists of science, programs, team, news and investor-relations material, and it publishes no developer program, public API, SDK, webhook surface or machine-readable specification of any kind.

Aardvark Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Clinical Trials.

Aardvark Therapeutics’ developer surface includes product news and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesClinical TrialsDrug DevelopmentRare DiseaseMetabolic Health

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 11.7/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.6 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/aardvark-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 3

The organization behind the API

Website

Website

News

News

InvestorRelations

InvestorRelations

Other 1

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: aardvark-therapeutics
name: Aardvark Therapeutics
description: 'Aardvark Therapeutics, Inc. is a Nasdaq-listed (AARD) clinical-stage biopharmaceutical company developing novel
  small-molecule therapies designed to inhibit hunger and treat metabolic disease. Its lead candidate, ARD-101, is an oral,
  gut-restricted agonist of bitter taste receptors (TAS2Rs) on the luminal side of the intestine, which triggers the release
  of satiety hormones to suppress hunger signaling; it has been evaluated for hyperphagia associated with Prader-Willi Syndrome,
  including the Phase 3 HERO trial, as well as in obesity and hypothalamic obesity. The company operates purely as a drug-development
  organization: its public web presence consists of science, programs, team, news and investor-relations material, and it
  publishes no developer program, public API, SDK, webhook surface or machine-readable specification of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/aardvark-therapeutics/refs/heads/main/apis.yml
image: https://i0.wp.com/aardvarktherapeutics.com/wp-content/uploads/2022/11/d-footer-logo.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Drug Development
- Rare Disease
- Metabolic Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Aardvark Therapeutics is a clinical-stage biopharmaceutical company whose product is a drug (ARD-101), not software
    — its entire site is a seven-page WordPress marketing presence (home, science, programs, team, news, contact, legal) with
    no developer, API or documentation section anywhere in its sitemap.
  evidence:
  - url: https://aardvarktherapeutics.com/openapi.json
    status: 404
  - url: https://aardvarktherapeutics.com/developers
    status: 404
  - url: https://aardvarktherapeutics.com/.well-known/agent-card.json
    status: 404
  - url: https://aardvarktherapeutics.com/page-sitemap.xml
    status: 200
  - url: https://api.github.com/orgs/aardvark-therapeutics
    status: 200
  checked: '2026-08-06'
common:
- type: DomainSecurity
  url: security/aardvark-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/aardvark-therapeutics-llms.txt
- type: Website
  url: https://aardvarktherapeutics.com/
- type: PrivacyPolicy
  url: https://aardvarktherapeutics.com/legal/privacy-policy/
- type: TermsOfService
  url: https://aardvarktherapeutics.com/legal/terms-of-use/
- type: Contact
  url: https://aardvarktherapeutics.com/contact/
- type: News
  url: https://aardvarktherapeutics.com/in-the-news/
- type: InvestorRelations
  url: https://ir.aardvarktherapeutics.com/
- type: GitHubOrganization
  url: https://github.com/Aardvark-Therapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/aardvark-therapeutics_stock/